# Applying CRISPR Technologies for the Treatment of Human Herpesavirus Infections: A Scoping Review
## 2 Methods
### Data Charting Process and Synthesis of Results
\begin{table}
\begin{tabular}{l l l} \hline \hline
**Virus Type** & \multicolumn{1}{c}{**Search**} & \multicolumn{1}{c}{**Number of Search**} \\ \hline \hline \multicolumn{3}{c}{**PubMed**} \\ \hline \hline \multirow{6}{*}{\begin{tabular}{l} Herpes simplex virus \\ type 1 and type 2/Human herpesvirus \\ 1 and 2 \\ \end{tabular} } & CRISPR* AND (herpes* OR HHV) & 422 \\ \cline{2-3}  & ((“Clustered Regularly Interspaced Short Palindromic Repeats”[MeSH]) OR & 202 \\  & (“CRISPR-Cas Systems”[MeSH]) AND “Herpesviridae”[MeSH] & 115 \\ \cline{2-3}  & & CRISPR* AND HSV & \\ \cline{2-3}  & & (“Clustered Regularly Interspaced Short Palindromic Repeats”[MeSH]) OR & \\ \cline{2-3}  & (“CRISPR-Cas Systems”[MeSH]) AND (“(Simplexvirus”[MeSH]) OR & 61 \\  & (“Herpesvirus 1, Human”[MeSH]) OR (“Herpesvirus 2, Human”[MeSH])) & \\ \cline{2-3}  & & CRISPR* AND (varicella-zoster virus OR VZV) & 5 \\ \cline{2-3}  & & (“Clustered Regularly Interspaced Short Palindromic Repeats”[MeSH]) OR & 2 \\  & (“CRISPR-Cas Systems”[MeSH]) AND “Herpesvirus 3, Human”[MeSH] & 2 \\ \hline \multirow{6}{*}{\begin{tabular}{l} Epstein-Barr virus/Human \\ herpesvirusirus 4 \\ \end{tabular} } & CRISPR* AND (Epstein-Barr virus OR EBV) & 136 \\ \cline{2-3}  & & (“Clustered Regularly Interspaced Short Palindromic Repeats”[MeSH] OR & 43 \\ \cline{2-3}  & (“CRISPR-Cas Systems”[MeSH]) AND “Herpesvirus 4, Human”[MeSH] & 43 \\ \cline{2-3}  & & CRISPR* AND (cyomegalovirusovirus OR CMV) & 148 \\ \cline{2-3}  & & (“Clustered Regularly Interspaced Short Palindromic Repeats”[MeSH]) OR & 27 \\ \cline{2-3}  & & (“CRISPR-Cas Systems”[MeSH]) AND “Cytomegalovirusovirus”[MeSH] & 0 \\ \hline \multirow{2}{*}{\begin{tabular}{l} Human herpesvirus 6 \\ \end{tabular} } & (“Clustered Regularly Interspaced Short Palindromic Repeats”[MeSH]) OR & \multirow{2}{*}{0} \\  & (“CRISPR-Cas Systems”[MeSH]) AND “Herpesvirus 6, Human”[MeSH] & & \\ \cline{2-3}  & & (“Clustered Regularly Interspaced Short Palindromic Repeats”[MeSH]) OR & \\ \cline{2-3}  & & (“CRISPR-Cas Systems”[MeSH]) AND “Herpesvirus 7, Human”[MeSH] & 0 \\ \cline{2-3}  & & CRISPR* AND ([PERSON]’s sarcoma-associated herpesvirus or KSHV) & 54 \\ \cline{2-3}  & & (“Clustered Regularly Interspaced Short Palindromic Repeats”[MeSH]) OR & 19 \\ \cline{2-3}  & & (“CRISPR-Cas Systems”[MeSH]) AND “Herpesvirus 8, Human”[MeSH] & \\ \hline \multicolumn{3}{c}{**Web of Science**} \\ \hline \hline \multicolumn{3}{c}{} & CRISPR* (All Fields) and herpes* (All Fields) & 316 \\ \cline{2-3}  & & CRISPR* (All Fields) and HHV* (All Fields) & 53 \\ \cline{2-3} \cline{2-3}  & & CRISPR* (All Fields) and HSV* (All Fields) & 174 \\ \cline{2-3}  & & \\ \cline{2-3}  & & CRISPR* (All Fields) and varicella-zoster virus (All Fields) & 6 \\ \cline{2-3}  & & CRISPR* (All Fields) and VZV (All Fields) & 5 \\ \hline \multirow{2}{*}{\
\begin{tabular}{l} Epstein-Barr virus/Human \\ herpesvirusitus 4 \\ \end{tabular} } & CRISPR* (All Fields) and Epstein-Barr virus (All Fields) & 166 \\ \cline{2-3}  & & CRISPR* (All Fields) and EBV (All Fields) & 98 \\ \hline \multirow{2}{*}{
\begin{tabular}{l} Human cytomegalovirusovirus/Human \\ herpesvirusitus 5 \\ \end{tabular} } & CRISPR* (All Fields) and cytomegalovirusovirus (All Fields) & 103 \\ \cline{2-3}  & & CRISPR* (All Fields) and CMV (All Fields) & 98 \\ \hline \multicolumn{3}{c}{} \\ \cline{2-3}  & & Included in the general search & 0 \\ \cline{2-3}  & & CRISPR* (All Fields) and [PERSON]’s sarcoma-associated herpesvirusirus (All Fields) & 44 \\ \cline{2-3}  & & CRISPR* (All Fields) and KSHV (All Fields) & 44 \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Overview of the searches performed in PubMed and Web of Science for each herpesvirus, with their associated number of search results. to provide a schematic overview of the main design characteristics of the experiments conducted in the included studies.